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preventing ventilator associated pneumonia
in an intensive care setting
Raquel A Caserta1*, Alexandre R Marra1, Marcelino S Durão1, Cláudia Vallone Silva2,
Oscar Fernando Pavao dos Santos3, Henrique Sutton de Sousa Neves4, Michael B Edmond5
and Karina Tavares Timenetsky1
Abstract
Background: Ventilator-associated pneumonia (VAP) is a common infection in the intensive care unit (ICU) and
associated with a high mortality.
Methods: A quasi-experimental study was conducted in a medical-surgical ICU. Multiple interventions to optimize
VAP prevention were performed from October 2008 to December 2010. All of these processes, including the
Institute for Healthcare Improvement’s (IHI) ventilator bundle plus oral decontamination with chlorhexidine and
continuous aspiration of subglottic secretions (CASS), were adopted for patients undergoing mechanical ventilation.
Results: We evaluated a total of 21,984 patient-days, and a total of 6,052 ventilator-days (ventilator utilization rate
of 0.27). We found VAP rates of 1.3 and 2.0 per 1,000 ventilator days respectively in 2009 and 2010, achieving zero
incidence of VAP several times during 12 months, whenever VAP bundle compliance was over 90%.
Conclusion: These results suggest that it is possible to reduce VAP rates to near zero and sustain these rates,
but it requires a complex process involving multiple performance measures and interventions that must be
permanently monitored.
Keywords: Ventilator associated pneumonia, Prevention, Intensive care, VAP bundle
Background
Ventilator-associated pneumonia (VAP) is a common in-
fection in the ICU. [1] Recent studies describe a rate of
1 to 4 cases per 1,000 ventilator-days, although this can
reach up to 10 cases per 1,000 cases ventilator-days in
neonates and surgical patients [2,3]. The improvement
in outcomes associated with recent initiatives suggest
that many cases of VAP can be prevented by adhering to
bundles of infection prevention measures [4,5].
The attributable mortality of VAP is around 4% to 9%
varying with definitions, case-mix, causative microorgan-
isms, and treatment adequacy [6,7]. VAP is also asso-
ciated with considerable morbidity, due to increased
length of hospital and ICU stay, prolonged mechanical
ventilation and increased hospital expenses [8-10], as
well as excessive utilization of antimicrobials with cor-
respondingly higher costs [8,9].
As part of the 5 Million Lives campaign, endorsed by
leading US agencies and professional societies, The Insti-
tute for Healthcare Improvement (IHI) recommends
that all ICUs implement a ventilator bundle to reduce
the incidence of VAP to zero [11]. Since 2007, we have
implemented the VAP bundle in our ICU, including oral
hygiene with 0.12% chlorhexidine and continuous aspir-
ation of subglottic secretions (CASS) [4]. With these
measures we were able to achieve zero incidence of VAP
during a few months when a higher than 95% compli-
ance rate with the VAP bundle was obtained [4]. How-
ever, to date there are no reports of sustained low
incidence of VAP [4] (near zero).
The purpose of this quasi-experimental study was to
evaluate whether the sustained implementation of the
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VAP bundle in our ICU could effectively reduce the inci-
dence of ventilator-associated pneumonia (VAP).
Methods
Setting and study design
An interrupted time series study was conducted in a 38-
bed medical-surgical intensive care unit (ICU) of a ter-
tiary care, private hospital in São Paulo, Brazil. This is
an open staffing model ICU where approximately 2,200
patients are admitted annually. This study was a quality
improvement study that was approved by the Institu-
tional Review Board of Hospital Israelita Albert Einstein
(IRB). The requirement for informed consent was
waived by our IRB in accordance with the Code of Fed-
eral Regulations and the Privacy Rule. This project was
carried out after our previously published study from
April 2007 to September 2008 [4]. Herein we report
our observations for the period from October 2008 to
December 2010 to evaluate whether the sustained imple-
mentation of the VAP bundle in our ICU could effect-
ively reduce the incidence of VAP. All these hospital
epidemiology data was analysed anonymously.
The VAP bundle included elevation of the head of the
bed (HOB) (30–45 degrees); daily “sedation vacations”
and assessment of readiness to extubate; peptic ulcer
disease prophylaxis; and deep venous thrombosis/
pulmonary thromboembolism (DVT/PE) prophylaxis
for all ICU patients requiring mechanical ventilation.
This ventilator bundle was monitored each weekday
by an ICU nurse. She intervened in this process while
performance monitoring was taking place at the bed-
side if non-compliance with an element of the bundle
was detected (e.g., sedation was not stopped). We also
intervened in other CDC evidence-based practices
for prevention of ventilator associated pneumonia [3] in-
cluding: 1) no routine changing of humidified ventilator
circuits, 2) periodically draining and discarding conden-
sate collecting in the ventilator tubing and, 3) changing
the heat-and-moisture exchangers (HMEs) when they
showed mechanical malfunction or became visibly
soiled. These CDC process measures were audited twice
yearly in a small sample of mechanically ventilated
patients at random intervals.
Other interventions to control VAP in the ICU were
implemented in October 2007 when oral decontamin-
ation with chlorhexidine 0.12% was introduced for all
mechanically ventilated ICU patients [4]. In February
2008, the continuous aspiration of subglottic secretions
(CASS) endotracheal tube was implemented for patients
requiring mechanical ventilation and expected to require
ventilation for longer than 24 hours [4].
Previously [4] we had compared the VAP bundle alone
(phase 1), with the VAP bundle + oral decontamination
with chlorhexidine 0.12% (phase 2), and the VAP bundle +
oral decontamination with chlorhexidine 0.12% + con-
tinuous aspiration of subglottic secretions (CASS) endo-
tracheal tube (phase 3). We then decided to analyze our
performance after almost two years of all these interven-
tions (including the VAP bundle) to determine whether
this was a sustainable program for controlling ventilator
associated pneumonia. We decided to extend data col-
lection in phase 3 (VAP bundle + oral decontamination
with chlorhexidine 0.12% + continuous aspiration of
subglottic secretions (CASS) endotracheal tube) to
evaluate this assumption (Figure 1). In summary, phases
1, 2 and 3 (from April 2007 to September 2008) are
a consequence of our previous publication [4]. We
extended data collection in this present manuscript
(from October 2008 to December 2010) in phase 3.
We provided monthly feedback on compliance with the
bundle components to the ICU team (doctors, nurses
and respiratory therapists). We also displayed posters
in the ICU with bar charts showing compliance with
the recommended procedures. These posters also
showed the VAP rate as determined in surveys con-
ducted by the Department of Infection Control and Hos-
pital Epidemiology.
Definitions
VAP surveillance was performed by trained infection
control specialists using the US Center for Disease
Control and Prevention/National Healthcare Safety Net-
work (CDC/NHSN) definition [12] in an independence
way from the treating ICU team, the incidence of VAP
was expressed as cases of VAP per 1,000 ventilator-days
and the incidence of ventilator associated tracheobron-
chitis (VAT) was expressed as cases of VAT per 1,000
ventilator-days.
VAP was defined as the sum of the clinical criteria as
described the presence of fever (temperature >38°C),
new or increased sputum production, in combination
with radiologic evidence of a new or progressive
Figure 1 Study design. *Phases 1, 2 and 3 (from April 2007 to
September 2008) are a consequence of our previous publication [4].
We extended data collection in this present manuscript (from
October 2008 to December 2010) in phase 3.
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pulmonary infiltrate, leukocytosis, a suggestive Gram’s
stain, and grow of bacteria (not necessarily) in cultures
of sputum, tracheal aspirate, pleural fluid, bronchoal-
veolar lavage (BAL), or blood [12]. Per the CDC/NHSN
definition, microbiological data are not necessary for
the diagnosis.
VAT was defined as the presence of fever (temperature
>38°C), new or increased sputum production, a micro-
biologically positive respiratory sample, and the absence
of pulmonary infiltrates on chest radiography.
Microbiological methods
All isolates were identified by manual or automated
methods and confirmed using the Vitek 2 system (bio-
Merieux Vitek, Inc., Hazelwood, MO).
Statistical analysis
The variables of interest were those that indicated com-
pliance with the VAP prevention measures. We used
segmented regression analysis of interrupted time series
[13] to assess the changes in VAP before and after im-
plementation of the ventilator bundle, oral decontamin-
ation with chlorhexidine 0.12%, and CASS endotracheal
tube for patients requiring mechanical ventilation,
according to the interventional phases (Figure 1).
We adjusted a segmented regression model that
allowed us to analyze a reduction (or an increase) in
VAP rate at each study phase separately: (1) ventilator
bundle only, April 2007 to October 2007; (2) ventilator
bundle + chlorhexidine, November 2007 to February
2008; (3) ventilator bundle + chlorhexidine + CASS
endotracheal tube, March 2008 to December 2010
(Figure 1).
The intercept and slope are the two parameters which
define each segment of a time series. The intercept is
the value of the series at the beginning of a given time
interval, the slope is the change of the measure (VAP
rate) over a certain period (e.g., a month). A change in
slope (β) is defined by an increase or decrease in the
slope of the time step after the intervention, compared
with the time step preceding the intervention. It is
important to mention that this is not the same as
constructing three models of simple linear regression,
because the third partition parameters depend on the
previous partitions’ parameters.
All tests of statistical significance were 2-sided with a
significance level set at 0.05. All the data analyses were
performed using SPSS 16.0 and SAS 9.1; SAS Institute
Inc, Cary, NC, USA.
Results
Compliance with process measures in each phase
In 2009, the process measures subject to analysis
included 2,396 HOB elevation observations (98.6%
compliance), 611 ventilator circuits without changes
(99.8% compliance) and 611 observations of HMEs
changes (95% compliance). Also included in the analysis
were 2,396 daily sedation vacations, gastric prophylaxis
opportunities and DVT/PE prevention opportunities
with 98%, 99% and 98% compliance, respectively. There
were also 611 observations of ventilator-circuit-tubing
condensate with 92% compliance. CASS was performed
in 342 patients since October 2008, and all patients
requiring mechanical ventilation received oral decon-
tamination with chlorhexidine 0.12% (Table 1).
In 2010, the analysis included 2,260 HOB elevation
observations (91% compliance), 390 ventilator circuits
without changes (99% compliance) and 390 observations
of HMEs changes (94% compliance). Daily sedation
vacations, gastric prophylaxis opportunities and DVT/PE
prevention opportunities had 2,486 observations with
91% of compliance in all measurements (Table 1).
Incidence density of VAP and in-hospital mortality
of VAP patients
The incidence density of VAP per 1,000 ventilator days
in the ICU was 1.3 in 2009 (10,889 patient-days) and in
2010 the incidence was 2 (11,095 patients-days). The
incidence density of VAT per 1,000 ventilator days in the
ICU was 1.0 (10,889 patient-days) in 2009 and in 2010
the incidence was 2 (11,095 patient-days).
Mechanical ventilation days, ICU length of stay, venti-
lator utilization ratio, number of VAPs, number of VATs,
ventilator-days, ventilator-free days, in-hospital mortality
of VAP patients and in-hospital mortality ICU patients
are shown in Table 1.
Getting to zero VAP for one or more months has
occurred since 2009 when there was greater than 95%
compliance with the ventilator bundle, oral decontamin-
ation with chlorhexidine 0.12% and continuous aspir-
ation of subglottic secretions (CASS) (Figure 2). In
addition to this we continued to evaluate ventilator
circuits without changes, HMEs changes and ventilator-
circuit-tubing condensate.
Segmented regression analysis (Figure 3) showed a sta-
tistically significant increase in VAP rate (β11 = +2.59;
p < 0.001) in the first segment (ventilator bundle). The
transition from the first segment (ventilator bundle) to
the second segment (ventilator bundle + chlorhexidine)
showed a significant decrease in VAP rate (β20 =−11.24;
p < 0.001). The slope (β21) in the second segment was
negative, indicating a reduction in VAP rate upon imple-
mentation of oral decontamination with chlorhexidine
(β21 =−2.30 with p = 0.272). The transition from the sec-
ond segment (ventilator bundle + chlorhexidine) to the
third segment (ventilator bundle + chlorhexidine +
CASS endotracheal tube) was not significant in VAP rate
(β30 =−2.67 with p = 0.682). In the third segment the
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slope (β31) was practically zero, indicating that there
was no reduction in VAP rate, which was maintained
along the segment (β31 = 0.03 with p = 0.610).
Microbiological features
As seen in Table 2, we had 10 cases of VAP, 4 in 2009
and 6 in 2010. Most patients were male (70%), with a
median age of 58 years old (range 20 to 85 years), the
median mechanical ventilation time was 9 days (range 5
to 33 days). Eighty percent of all the microorganisms
identified were gram-negative, followed by viruses (10%),
and 10% unidentified microorganisms.
Pseudomonas aeruginosa accounted for over 40%
of the gram-negative pathogens. The most prevalent
pathogens overall were Pseudomonas aeruginosa and
Acinetobacter baumannii. The majority of the pathogens
were identified by tracheal aspiration. Only 25% of VAP
patients (1/4) were investigate by BAL (Table 2).
The mortality rate was 100% for the patients with VAP
in 2009 and 83.3% in 2010.
Mechanical ventilation
The total time of mechanical ventilation was 6,052 days,
with a utilization rate of 28% in 2009 and 27% in 2010
(Table 1). As seen in Figure 4, our mechanical ventila-
tion utilization rates have been reduced since 2000, with
a 17% drop from 2000 to 2010.
Table 1 Characteristics of the sustained period of “getting to zero” VAP prevention program in the ICU
2009 2010
Patient-days (total) 10,889 11,095
Number of patients 2,705 2,717
Age, mean ± SD (in years) 67±19 66±18
Male, n (%) 1,571 (58.1%) 1,587 (58.4%)
APACHE, mean ± SD 18±6 18±7
Ventilator-days (total) 3,009 3,043
Ventilator utilization ratio 0.28 0.27
MV days – median (IQR) 4 (1–22) 3.7 (1–23)
Ventilator-free days 7,880 8,052
ICU LOS days – mean ± SD 3.9±0.4 4.0±0.3
Compliance with process measures, n (%)
HOB observations 2362/2396 (98.6%) 2260/2486 (90.9%)
Daily “sedation interruptions” 2358/2396 (98.4%) 2273/2486 (91.4%)
Gastric prophylaxis 2393/2396 (99.9%) 2276/2486 (91.5%)
DVT/PE prevention 2363/2396 (98.6%) 2266/2486 (91.1%)
Ventilator circuits without changes 610/611 (99.8%) 387/390 (99.2%)
HMEs changed 584/611 (95.5%) 368/390 (94.3%)
Ventilator-circuit-tubing condensate 564/611 (92.3%) 360/390 (92.3%)
CASS endotracheal tube - n 342 311
Number of VAPs 4 6
Number of VATs 3 6
VAP rate per 1,000 ventilator-days 1.3 2.0
VAT rate per 1,000 ventilator-days 1.0 2.0
In-hospital mortality in VAP patients, n (%) 4/4 (100) 5/6 (83)
In-hospital mortality in ICU patients, n 196 220
In-hospital mortality in ICU patients per 10,000 patient days 180 198
CASS Continuous Aspiration of Subglottic Secretions.
DVT/PE Deep Venous Thrombosis/Pulmonary Embolism.
ICU LOS Intensive Care – Length of Stay.
HMEs Heat-and-Moisture Exchanges.
HOB Head of the Bed.
MV Mechanical Ventilation.
SD Standard Deviation.
VAP Ventilator Associated Pneumonia.
VAT Ventilator Associated Tracheobronchitis.
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Discussion
Since 2007, we have set as a priority in our hospital the
eradication of nosocomial infections. To this end, we
have developed a set of best practices for prevention of
ventilator associated pneumonia (VAP). In order to
achieve a reduction in VAP rates, we have applied the
Institute for Healthcare Improvement bundle model and
also implemented other preventive measures (oral chlor-
hexidine 0.12% and CASS endotracheal tube). Our VAP
rates are discussed on a monthly basis at a multidiscip-
linary meeting with our hospital’s chief executive officer
(CEO) and other senior management representatives re-
sponsible for ensuring that healthcare practices support
a program for infection prevention and control that ef-
fectively prevents VAP.
Many hospitals have achieved the goal of getting VAP
to zero [14,15], while others have managed to substan-
tially reduce VAP rates, but believe that eliminating VAP
in the intensive care unit may be an unrealistic goal [16].
In a previous publication [4], we have shown that this
was only possible when the compliance with the VAP
prevention bundle exceeded 95%, the CASS endo-
tracheal tube was incorporated in daily practices and
[17,18] oral hygiene with chlorhexidine was implemen-
ted [19]. In a recent systematic review and meta-analysis
of patients at risk for ventilator-associated pneumonia,
the use of endotracheal tubes with subglottic secretion
drainage was shown to effectively prevent ventilator-
associated pneumonia and to be possibly associated with
reduced duration of mechanical ventilation and length
Figure 3 Segmented regression of ventilator associated pneumonia (VAP) rate per 1,000 ventilator days from April 2007 to December
2010. Segmented 1: β10 =+6.08 p = 0.004; CI 95%: [(2.06 - 10.12)]. Segmented 1 (the slope): β11 =+2.59 p <0.001; CI 95%: [(1.47 - 3.71)].
Segmented 2: β20 =−11.24 p = 0.004; CI 95%: [(−18.60) - (−3.89)]. Segmented 2 (the slope): β21 =−2.30 p = 0.272; CI 95%: [(−6.48) - 1.88)].
Segmented 3: β30 =−2.67 p= 0.682; CI 95%: [(−15.83) - 10.47)]. Segmented 3 (the slope): β31 =+0.03 p= 0.610; CI 95%: [(−0.08) - 0.13)].
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of ICU stay [18]. We believe this might be the reason for
our reduced time and utilization rate of mechanical ven-
tilation, together with the daily sedation vacation
included in the VAP bundle. We also believe that obtain-
ing the commitment of all members of the ICU team
was ultimately a factor in our success in the implemen-
tation of these procedures over the years.
Klompas et al. [20] have called attention to the pro-
blems that may arise when we use VAP as a quality indi-
cator, including difficulties with the subjectivity implied
by the current VAP definition. Moreover, Edmond has
pointed out that the “getting to zero” approach may be
associated with adverse unintended consequences [21].
Moreover, the CDC/NHSN definition has been shown
to have lower sensitivity than the American College
of Chest Physicians definition [22]. Even though we
consider it important to report VAP rates, we believe we
should continuously report our compliance to the pre-
vention measures (VAP bundle) and the adverse events
associated with mechanical ventilation in ICU patients
[23]. However, we were able to show that the procedures
implemented since 2007 have contributed to a signifi-
cant reduction in our infection rates (Figure 5) and to a
decrease in the use of mechanical ventilation in recent
years (Figure 4). It is important to note that our VAP
surveillance was performed by trained infection control
practitioners using the US Centers for Disease Control
and Prevention/National Healthcare Safety Network
(CDC/NHSN) definition [12] throughout the study
period. Even though we have failed to demonstrate a sta-
tistically significant result using the segmented regres-
sion analysis of VAP prevention, we have achieved a
Table 2 Characteristics of infections causing VAP during the sustained period of “getting to zero” VAP prevention
program
N Year Age Gender Diagnostic MV time
(days)
Respiratory specimen Pathogen Clinical outcome
1 2009 85 Male DLOC/Hyponatremia 16 Tracheal aspirate P.aeruginosa Death
2 2009 65 Female Hypereosinophilia/ Myelopathy 5 BAL + Tracheal aspirate Acinetobacter baumannii Death
3 2009 20 Male Correction of GERD 19 Tracheal aspirate P.aeruginosa Death
4 2009 23 Female Liver failure/ liver transplant 5 Tracheal aspirate Acinetobacter lwoffii Death
5 2010 56 Male Respiratory failure/ BCP 16 Tracheal aspirate P.aeruginosa Death
6 2010 62 Male Carotid stenosis/ Endarterectomy 8 Tracheal aspirate S.marcescens Hospital discharge
7 2010 59 Male Chagas cardiomyopathy 10 Tracheal aspirate E.cloacae Death
8 2010 55 Female Hepatic encephalopathy 8 Nasopharyngeal swab RSV Death
9 2010 61 Male Acute respiratory failure/ BCP 33 Tracheal aspirate K.pneumoniae + P.aeruginosa Death
10 2010 58 Male Cranial trauma 7 Tracheal aspirate E.aerogenes + A.baumannii Death
MV Mechanical Ventilation.
DLOC Decreased Level Of Consciousness.
GERD Gastroenteral Reflux Disease.
RSV Respiratory Syncytial Virus.
BCP Bronchopneumonia.
BAL Bronchoalveolar lavage.
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Figure 4 Secular trends of mechanical ventilation utilization rate in ICU.
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zero infection rate by applying all the VAP prevention
measures recommended in the literature [8,9].
There are several limitations to this study. This is not
a randomized trial but a quasi-experimental, interrupted
time series study. Quasi-experimental study designs are
frequently used when it is not logistically feasible to con-
duct a controlled trial. Thus, other unmeasured factors
might have coincided with the interventions effective
since April 2007 (implementation of the ventilator bun-
dle), resulting in a decrease in VAP rates in our ICU.
However, this seems unlikely because there had been no
decrease in VAP rates over the previous several years
(Figure 5). Data from our ICU in 2011 and in the first
quarter of 2012 have shown that the VAP rate continues
low (1.5 and 1.9, respectively). Finally, as this interven-
tion was performed at a single medical center, it might
be inappropriate to extrapolate our results (i.e. VAP
mortality) to other hospitals. Even considering some
aspects as the attributable mortality of VAP, other
studies applying more sophisticated analysis such as
multistate model that appropriately handle VAP as a
time-dependent event or competing risk survival analysis
have shown rates of attributable mortality as low as 10%
[6,24]. Despite these limitations, our study further sup-
port the assumption that controlling VAP rates can be a
sustained with the monitoring of multiple performance
measures and quality improvement efforts.
Conclusions
The process and the outcome measures for VAP pre-
sented here are derived from published guidelines and
other relevant literature. While we recognize that the
VAP definition may be subject to criticism due to its
many subjective aspects, we managed to keep the whole
team’s commitment to preventive measures for over two
years, which demonstrates this is a sustainable program
for preventing ventilator-associated pneumonia in the
intensive care unit.
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